A clinical trial has revealed that individuals with type 2 diabetes can lower their risk of cardiovascular and renal conditions by taking a weekly dose of efpeglenatide.
The AMPLITUDE O trial studied the effect of the glucose-reducing injectable drug on more than 4,000 people with type 2 diabetes in 28 countries, according to the American Diabetes Association (ADA).
“We are encouraged that this once-a-week injection safely and effectively reduced cardiovascular and progression of kidney disease in patients with long-standing diabetes who had a high prevalence of cardiovascular and kidney disease,” Hertzel Gerstein, professor at McMaster University and Hamilton Health Sciences and deputy director of Canada’s Population Health Research Institute, told the ADA.
Patients assigned to weekly injections of efpeglenatide vs. placebo over a span of two years saw a 27% lower risk of a heart attack, stroke or cardiovascular death, and a 32% lower risk of kidney disease progression, the ADA reported.
Ninety-eight percent of adults with type 2 diabetes have at least one comorbid chronic condition, according to the ADA.
The findings from the AMPLITUDE O trial were published in The New England Journal of Medicine. The data was also presented virtually at ADA’s 81st Scientific Sessions.
